Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next

Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous swelling attacks. The biotech aims to have its ...